CN103897174A - Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof - Google Patents
Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof Download PDFInfo
- Publication number
- CN103897174A CN103897174A CN201210572818.1A CN201210572818A CN103897174A CN 103897174 A CN103897174 A CN 103897174A CN 201210572818 A CN201210572818 A CN 201210572818A CN 103897174 A CN103897174 A CN 103897174A
- Authority
- CN
- China
- Prior art keywords
- uregit
- preparation
- purposes
- compound
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a non-linear polymer containing an ethacrynic acid structure, a preparation method thereof and applications thereof. A compound with a branch structure is adopted to frame a novel non-linear polymer. The novel non-linear polymer and ethacrynic acid are subjected to valence bond linkage so as to produce a novel compound. The ethacrynic acid-coupled non-linear polymer has better effects on protecting optic nerves than medicines or medicaments in other forms.
Description
Technical field
The invention discloses the polymkeric substance that contains Uregit structure and preparation method and the purposes of polymkeric substance.
Background technology
Uregit is clinical in congestive heart failure, acute lung edema, renal edema, liver cirrhosis and ascites, hepatic ascites, schistosomicide ascites, cerebral edema and other oedema.Uregit is widely used at present, and the present invention gets up to form new compound by itself and L halfcystine and polymkeric substance coupling, is used for the treatment of glaucoma, and effect is splendid.
Glaucoma is a kind of illness in eye of irreversible blinding.By the end of 2012, there are in the world 6,500 power people to suffer from glaucoma, wherein 4,005 million peoples are primary open angle glaucomas, 1,005 million peoples are primary angle-closure glaucomas.A glaucomatous main blinding factor is exactly that intraocular pressure (intraocular pressure, IOP) raises.At present, mainly treat glaucoma from two aspects, the one, reduce intraocular pressure, thereby its mechanism of action is to reduce intraocular pressure by promoting aqueous humor drainage, the generation of minimizing aqueous humor and height to ooze dehydration; The 2nd, protection optic nerve; Deterioration of Optic Nerve in Glaucoma finally causes visual function to be lost; optic nerve protection treatment measure comprises reduction intraocular pressure, uses calcium antagonist, antioxidant; immunotherapy; supplement and alternative medicine, potential cytothesis and gene therapy, be not that all optic nerve protection means all can be used for clinical; much, still in the experimental study stage, its effect is not good enough.Uregit coupling segmented copolymer of the present invention, can make the new texture that contains Uregit of preparation dissolve in water, well controls drug delivery amount, and then reaches treatment glaucoma disease or derivative optic nerve injury illness.
The polymkeric substance that contains Uregit of preparing at this patent in treatment when glaucoma and polymkeric substance simply wrap up the nanometer formulation that Uregit makes and compare, the effect of drugs that this patent is invented far surmounts polymkeric substance and simply wraps up the nanometer formulation of Uregit, and medication effect is very good.
Summary of the invention
Of the present invention theing contents are as follows:
The segmented copolymer that the invention discloses the Uregit coupling shown in following formula I, its structure is as follows:
The wherein integer of m=1-500, preferably 1-300, the integer between n=1-200; The preferably integer between n=1-100.
The preparation method of multipolymer of the present invention, is characterized in that:
1) the sebacic acid reaction of the 6 arm polyoxyethylene glycol A that contain hydroxyl ending and ethanoyl obtains polymer B, the wherein integer of m=1-500, preferably 1-300; N=1-300, preferably 1-200
3) polymer B is reacted and is obtained final product with the C that contains Uregit;
Compd A;
Polymer B;
Containing the C of Uregit
The compound that wherein contains Uregit C is selected from Uregit and reacts gained Uregit coupling Cys with Cys.Wherein the described chemical step optional solvents of synthetic final product is selected from: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
The compound of new system can be prepared into the nanometer formulation that is suitable for topical, microball preparation.Purposes is the medicine of the preparation glaucomatous medicine for the treatment of and neuroprotective.
Preparation method of the present invention is specific as follows:
1) sebacic acid is refluxed in diacetyl oxide, form ethanoyl-sebacic acid;
2) ethanoyl-sebacic acid is mixed to reaction at 100-200 ℃, reaction times 10min to 10h with the 6 arm polyethylene glycol compound A that end up with hydroxyl; After question response mixture is cooling, washing, the dry polymer B that obtains;
3) Uregit is dissolved under low PH, slightly high pH value reacts with Cys, and freeze-drying after jolting 1h-5h, obtains C stand-by gently;
4) by the C that contains Uregit structure and polymer B as for 1-96 hour in solvent, after ultrasonic reaction 1-30 minute, in baking oven, foster and obtain formula I polymkeric substance, then homogenizer high-speed stirring 1-10 minute in subzero 30 ℃ of 0-, rotation volatilization obtains crude product, and aftertreatment obtains the nanometer formulation of end product formula I polymkeric substance.
Its reaction equation is as follows:
Compd A;
Polymer B;
Then, next must contain the C of Uregit
Generate
The polymkeric substance that what the present invention obtained contain Uregit structure, is easy to dissolve in water, and its transformation period extend much than Uregit, this base polymer is splendid in treatment glaucoma kind effect, obvious in the effect of protection optic nerve.
The nanometer formulation that the end product of preparing at this patent is made levy treatment eye disease relatively in, the medication effect of this patent polymkeric substance is very good, surmounts the nanometer formulation that is directly wrapped up Uregit (not with Uregit coupling) by polymkeric substance completely.
Accompanying drawing explanation:
The nuclear magnetic resonance map of the end product of Fig. 1 embodiment 1.
Nanoparticle, the sebacic acid-glycol copolymer that Fig. 2 embodiment 1 makes directly wraps up medicine accumulative releasing degree and the time chart of Uregit nanoparticle and Uregit ordinary preparation.
Nanoparticle, the sebacic acid-glycol copolymer that Fig. 3 embodiment 1 makes directly wraps up nanoparticle that Uregit the makes comparison diagram in the provide protection of optic nerve
Embodiment
Specific embodiment is described in further detail the present invention below, but the present invention not only limits to following examples.Preparation Example is as follows:
Embodiment 1
1) mixture of sebacic acid 100g in 700ml diacetyl oxide refluxes, to form ethanoyl-sebacic acid;
2) by the 1st) step product and mix and put into flask with 6 arm polyoxyethylene glycol 5g of hydroxyl ending, at 180 ℃, decompression contains intermingle with reaction 1 hour; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and also dry by petroleum ether;
3) be that dissolve at 5.2 places by Uregit 1.4g at PH, heighten pH value and be 7.4 and react with Cys, after jolting 3h, after freeze-drying, obtain Uregit-Cys gently stand-by;
4) the 800mg polymkeric substance of 200mg Uregit-Cys and step 3 is put into the dichloromethane solution 48 hours of 10ml dimethyl sulfoxide (DMSO) and 10ml; Ultrasonic 5 minutes; Then insert in baking oven 1 hour; In subzero 10-20 degree, homogenizer ultra-high speed stirs 3 minutes, then puts into 2% polyvinyl alcohol solution 600 and turns and stir 3 hours; Freeze-drying after centrifugal collection, obtains the nanoparticle of end product.
Embodiment 2
1) mixture of sebacic acid 60g in 800ml diacetyl oxide refluxes, to form ethanoyl-sebacic acid;
2) by the 1st) step product and mix and put into flask with 6 arm polyoxyethylene glycol of hydroxyl ending, at 180 ℃, decompression contains intermingle with reaction 1 hour; Treat that polymkeric substance is cooled to room temperature chloroform and dissolves, and also dry by petroleum ether;
3) be that dissolve at 5 places by Uregit 1g at PH, heighten pH value and be 7.2 and react with Cys, after jolting 2h, after freeze-drying, obtain Uregit-Cys gently stand-by;
4) 30mg Uregit-Cys and this polymkeric substance 150mg are put into the solution being mixed by 1ml methyl alcohol and 1ml methylene dichloride; Ultrasonic 2 minutes; Then insert in baking oven 24 hours; In subzero 10-20 degree, homogenizer high-speed stirring 2 minutes, product is put into 3% cholic acid solution 600 and is turned and stir 4 hours; Freeze-drying after centrifugal collection, obtains the microballoon of novel polymer.
Effect experiment is as follows:
Sample prepared by embodiment 1-2 and and sebacic acid-glycol copolymer directly the nanoparticle medicine group of the Uregit of parcel (there is not chemical coupling reaction; Uregit does not have structural changes), Uregit ordinary preparation (powder injection) carries out respectively the drug action test of stability test, drug release in vitro test and letter out eye and neuroprotective.
Stability test:
By the nanoparticle medicine group of the Uregit of 1 group of sample of preparing of embodiment and sebacic acid-glycol copolymer parcel, Uregit ordinary preparation is got with amount (in order to uricometer) and is measured respectively absorbance.Then put into 20 degree incubator 3 months for three groups, take out subsequently and measure absorbance under 270 nanometers, the absorbance front and back of the Uregit of the visible embodiment 1-2 group of result and ordinary preparation group are without changing, and the nanoparticle group absorbancy of parcel decline 17%.
Drug release in vitro test:
By 1 group of embodiment, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the Uregit of parcel and Uregit ordinary preparation component have another name called get equivalent medicine (in order to uricometer, every group containing 10mg Uregit), then by each group of medicine as in test tube, after soaking with PBS damping fluid, 37 degrees Celsius of lower joltings in shaking table, after timing sampling, under ultraviolet spectrophotometer 270 nanometers, measure the content of medicine, and the medicament contg per-cent that after record, calculating discharges, do releasing curve diagram, X-coordinate be the time (my god), ordinate zou is the per-cent discharging.See Fig. 2, the medicine that visible embodiment discharges is more permanent, makes drug half-life longer.
Solubility test in water:
By embodiment 1-2 group, sebacic acid-glycol copolymer directly the nanoparticle medicine group of the Uregit of parcel and Uregit ordinary preparation component have another name called get equivalent medicine (in order to uricometer, every group containing 100mg Uregit), put into respectively test tube, with the dissolving of 10mlPBS damping fluid jolting, situation is dissolved in static rear observation.The dissolved state that records 3 minutes and 20 minutes, result is as follows.
The comparison of table 1 solubleness
Treatment experiment to rat angle closure glaucoma:
1.1 laboratory animal and grouping
Experiment adopts Thirty male rats, body weight 220g left and right.Before modeling, by animal random packet: i.e. blank group; Model group; Embodiment 1-2 group, polymkeric substance directly wraps up Uregit group, and common Uregit preparation group is administered once every 5 days intraocular injections, dosage 0.1mg injection/kg; Positive drug group selection pilocarpine eye drop, be administered once every day, one time one.All administrations continue 15 days.
The foundation of 1.2 animal models
Abdominal injection rat 4% Chloral Hydrate (200mg.kg-1) before experiment, then uses 1% lignocaine toponarcosis cornea of rats.During high intraocular pressure, keep every half an hour 0.2 milliliter of abdominal injection 4% Chloral Hydrate make the state of animal continuous narcosis.Adopt pulley-suture system that rat right eye intraocular pressure is raise, left side eyeball contrasts simultaneously.Be respectively an identical heavy counterweight by surgical sutures two ends, hitch a circle in the middle of suture for around after rat canthus limbus of sclera 2 millimeters, the counterweight at two ends is exerted pressure to rat eyes continually and steadily by pulley.It is 20 grams that counterweight is exerted pressure, and continuous 6 hours causes rat angle closure glaucoma model.Raise and measured rathole pressure record to the 15th day.
1.3 experimental result
Experimental result is in table 2
The intraocular pressure result (mmHg, n=10) of glaucoma rat under the each group of table 2 drug treatment
With model group comparison
*p < 0.05
*p < 0.01
Provide protection experiment to optic nerve:
2.1 laboratory animal and grouping
Experiment adopts Adult female rats, body weight 200g left and right.By animal random packet: i.e. blank group; Model group; Embodiment 1-2 group, polymkeric substance directly wraps up Uregit group, and common Uregit preparation group is administered once every 5 days intraocular injections, and dosage 0.1mg injection/kg finishes after 20 days to observe.
The foundation of 2.2 animal models
Carry out abdominal injection rat 6% Chloral Hydrate (200mg.kg-1) anesthesia before the preparation experiment of nerve injury model according to the method for the people such as Chen Xiaorui report, the local cleaning-sterilizing of eye, go in ring and cut off outer canthus portion bulbar conjunctiva, open Tenons capsule, blunt separation Suspensory ligament, tractive eyeball forward, exposes optic nerve, eye scissors 2mm place after ball enters the vertical optic nerve that cuts off in socket of the eye and causes optic nerve injury, avoids damaging optical fundus blood vessel.Guarantee consistence, all optic nerve transections hinders all in identical position, and stitch ball conjunctiva is also received eyeball, painting Antibiotic Eye Ointment.Within postoperative 2 days, occur Marcus-gun pupil, eyeball is without obviously outstanding, and catacleisis is complete, and eyeground is successful model without obvious bleeder.False wound eye only separates and exposes optic nerve, not all right cross-section wound.Administration was won eyeball after 20 days.After disconnected neck is put to death, win whole eyeball (retaining ball optic nerve 2mm), make the capable electron microscopic observation of sample.The results are shown in Figure 3, the effect that the neural action effect of visible embodiment protection is better than polymkeric substance far away and directly wraps up Uregit neuroprotective.
Claims (9)
1. in the structure being shown below, contain the polymkeric substance of Uregit, its structure is as follows:
2. the multipolymer of claim 1, the wherein integer of m=1-500, preferably 1-300, the integer between n=1-200; The preferably integer between n=1-100.
3. the preparation method of multipolymer as claimed in claim 1, is characterized in that:
1) obtain compd A with methoxy poly (ethylene glycol) amine and citric acid reactions;
2) reaction of the sebacic acid of compd A and ethanoyl obtains polymer B, the wherein integer of n=1-200, preferably 1-100;
3) polymer B is reacted and is obtained final product with the C that contains Uregit;
Containing the C of Uregit.
4. preparation method claimed in claim 3, the compound that wherein contains Uregit C is selected from Uregit and reacts gained Uregit coupling Cys with Cys.
5. the method for claim 3 or 4, wherein said chemical step is optionally selected from solvent: one or more in benzene, toluene, pyridine, tetrahydrofuran (THF), chloroform, tetracol phenixin, methylene dichloride, methyl alcohol, ethanol, methylene dichloride, dimethyl sulfoxide (DMSO), DMF.
6. the compound of claim 1 can be prepared into the nanometer formulation that is suitable for topical, microball preparation.
7. the purposes of the compound of claim 1, purposes is the medicine of preparation treatment eye disease.
8. the purposes of the compound of claim 1, purposes is to prepare the medicine of neuroprotective.
9. the purposes of claim 6, wherein eye disease refers to glaucoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210572818.1A CN103897174A (en) | 2012-12-26 | 2012-12-26 | Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210572818.1A CN103897174A (en) | 2012-12-26 | 2012-12-26 | Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103897174A true CN103897174A (en) | 2014-07-02 |
Family
ID=50988775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210572818.1A Pending CN103897174A (en) | 2012-12-26 | 2012-12-26 | Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103897174A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018503736A (en) * | 2015-01-20 | 2018-02-08 | ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | Composition for sustained release of anti-glaucoma agent that suppresses intraocular pressure |
| US10098965B2 (en) | 2015-09-22 | 2018-10-16 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| US11426345B2 (en) | 2015-01-27 | 2022-08-30 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| US11548861B2 (en) | 2017-03-23 | 2023-01-10 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
-
2012
- 2012-12-26 CN CN201210572818.1A patent/CN103897174A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| BARBARA VOITH ET AL: "New specific and sensitive HPLC-assays for ethacrynic acid and its main", 《 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
| GRAZYNA CYNKOWSKA ET AL: "Novel antiglaucoma prodrugs and codrugs of ethacrynic acid", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| NA ZHANG ET AL: "Synthesis of Three Types of Amphiphilic Poly(ethylene", 《MACROMOL. CHEM. PHYS》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| JP2018503736A (en) * | 2015-01-20 | 2018-02-08 | ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | Composition for sustained release of anti-glaucoma agent that suppresses intraocular pressure |
| US11426345B2 (en) | 2015-01-27 | 2022-08-30 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| US10098965B2 (en) | 2015-09-22 | 2018-10-16 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US10111964B2 (en) | 2015-09-22 | 2018-10-30 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US10117950B2 (en) | 2015-09-22 | 2018-11-06 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US10159747B2 (en) | 2015-09-22 | 2018-12-25 | Graybug Visioon, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US10485876B2 (en) | 2015-09-22 | 2019-11-26 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| US11548861B2 (en) | 2017-03-23 | 2023-01-10 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| US11160870B2 (en) | 2017-05-10 | 2021-11-02 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103897174A (en) | Novel polymer containing ethacrynic acid structure, preparation method thereof and applications thereof | |
| CN103833998A (en) | Novel compound with ethacrynic acid structure as well as preparation method and application of novel compound | |
| CN107982212A (en) | A kind of atropic category medicament slow release eye drops and preparation method thereof | |
| CN103910868B (en) | Non-linear polymer and preparation method and purposes containing Doxorubicin structure | |
| CN103848986B (en) | Compound and preparation method and purposes containing cephalosporin structure | |
| CN103910867A (en) | Nonlinear polymer having doxorubicin structure, and preparation method and application thereof | |
| CN103848985B (en) | Noval chemical compound and preparation method and purposes containing Sutent analog structure | |
| CN103833997A (en) | New compound with tozasertib structure as well as preparation method and application thereof | |
| CN103834003A (en) | New compound containing xalkori structure, preparation method thereof and application | |
| CN103848901A (en) | New compound containing vancomycin structure as well as preparation method and application thereof | |
| CN103830741B (en) | Compound and preparation method and purposes containing tazatide analog structure | |
| CN103865056B (en) | Non-linear polymer and preparation method and purposes containing Doxorubicin structure | |
| CN103910873A (en) | Doxorubicin structure-containing star-shaped polymer and preparation method and use thereof | |
| CN103910872A (en) | Doxorubicin structure-containing star-shaped polymer and preparation method and use thereof | |
| CN103848894A (en) | Novel compound containing daptomycin structure as well as preparation method and application thereof | |
| CN103910866B (en) | Noval chemical compound and preparation method containing anthracycline antibiotic structure and purposes | |
| TW200918075A (en) | Compositions and methods for modulating endophthalmitis using fluoroquinolones | |
| CN103897041A (en) | Novel compound containing vancomycin structure and preparation method and use thereof | |
| CN103910869A (en) | Nonlinear polymer having doxorubicin structure, and preparation method and application thereof | |
| CN103897173B (en) | Non-linear polymer and preparation method and purposes containing Doxorubicin structure | |
| CN101759741B (en) | Compound and application thereof in preparation of medicine for treating angiogenesis | |
| CN103980480A (en) | Preparation and use of drug grafted polymer | |
| CN104109247B (en) | A kind of preparation and use of the polymer containing Doxorubicin structure | |
| CN104119339A (en) | Compounds reducing intraocular pressure, and preparation method and application thereof | |
| CN105330669A (en) | 2-amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-formic acid polymorphic substance, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140702 |